Pharming Group N.V. (AMS: PHARM)
Netherlands
· Delayed Price · Currency is EUR | Market Cap | 475.87M |
| Revenue (ttm) | 256.20M |
| Net Income (ttm) | -15.98M |
| Shares Out | 678.35M |
| EPS (ttm) | -0.02 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,972,710 |
| Open | 0.700 |
| Previous Close | 0.702 |
| Day's Range | 0.683 - 0.700 |
| 52-Week Range | 0.648 - 1.220 |
| Beta | 0.84 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 24, 2024 |
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-1... [Read more]
News
Morgan Stanley's Strategic Acquisition of Pharming Group Shares
Morgan Stanley's Strategic Acquisition of Pharming Group Shares
Pharming Group to participate in November investor conference
Leiden, the Netherlands, November 5, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor con...
Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript
Pharming Group N.V. 2024 Q3 - Results - Earnings Call Presentation
Pharming reports Q3 results
Pharming Group reports Q3 GAAP EPS of $0.002 and revenue of $74.8M, showing a 12.1% year-over-year increase.
Pharming Group to report third quarter 2024 financial results on October 24
Leiden, the Netherlands, October 10, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) third quarter 2024 financial re...
Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation
Proof of concept clinical trial will evaluate leniolisib in PIDs with immune dysregulation linked to altered PI3Kẟ signaling in lymphocytes
Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, Septem...
Pharming Group to participate in September investor conferences
Leiden, the Netherlands, September 4, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor co...
Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript
Pharming Group NV (NASDAQ:PHAR) Q2 2024 Earnings Conference Call August 1, 2024 7:30 AM ET Company Participants Sijmen de Vries - CEO & Executive Director Stephen Toor - Chief Commercial Officer Anur...
Pharming Group reports second quarter and first half 2024 financial results and provides business update
Leiden, the Netherlands, August 1, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the second...
Pharming Group to report second quarter and first half 2024 financial results on August 1
Leiden, the Netherlands, July 18, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) second quarter and first half 2024...
Pharming Group to participate in June investor conferences
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor confere...
Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European Union
L eiden , the Netherlands, May 30, 2024 : Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today an update on the ongoing review of its Marketing Au...
Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
Leiden, the Netherlands, May 21, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM/Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, a...
Pharming Group to participate in May investor conference
Leiden, the Netherlands, May 20, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor confere...
Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025
THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF BONDHOLDERS. IF BONDHOLDERS ARE IN ANY DOUBT AS TO THE ACTION THEY SHOULD TAKE, THEY SHOULD SEEK THEIR OWN FINANCIAL AND LEGAL ADVICE I...
Pharming Group N.V. (PHAR) Q1 2024 Earnings Call Transcript
Pharming Group N.V. (NASDAQ:PHAR) Q1 2024 Earnings Conference Call May 8, 2024 7:30 AM ET Company Participants Sijmen de Vries - Executive Director and Chief Executive Officer Stephen Toor - Chief Co...
Pharming Group reports first quarter 2024 financial results and provides business update
Leiden, the Netherlands, May 8, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) presents its preliminary (unaudited) financial report for the three m...
Pharming Group to report first quarter 2024 financial results on May 8
Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2024 financial resu...
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized
Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Pharming Group announces the placement of €100 million convertible bonds due 2029
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES OR IN OR INTO AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW.
Pharming announces completion of enrollment in pediatric clinical trial of leniolisib
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency